肺癌多发性骨转移疼痛治疗的临床观察  

Clinical observation on patients with lung cancer with painful multiple bone metastases

作　　者：黄瑞文[1] 李勇[1] 陈思现[1] 李绮云[1] 

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《宁夏医学杂志》2006年第6期422-424,共3页Ningxia Medical Journal

摘　　要：目的观察153Sm-乙二胺四甲基膦酸(153Sm-EDTMP)联合帕米膦酸二钠治疗肺癌多发性骨转移疼痛的疗效及毒副作用。方法将102例肺癌多发性骨转移疼痛患者,随机分为联合组(153Sm-EDTMP联合帕米膦酸二钠)1、53Sm-EDTMP内照射组,帕米膦酸二钠组,分别观察骨痛缓解效果及毒性反应。结果联合组缓解骨痛总有效率为91.4%,153Sm-EDTMP内照射组为68.6%,帕米膦酸二钠组为65.6%,联合组明显高于另外两组,差异均有显著性统计学意义(P<0.05)。3组均无严重的毒副作用。结论153Sm-EDTMP联合帕米膦酸二钠治疗肺癌多发性骨转移疼痛能提高疗效,不良反应小,值得临床推广使用。Objective To observe the efficacy and toxicity of samaritan- 153 ethylene diamine teramethylene phosphonate（^153Sm - EDIMP） and pamidronate as treatment for patients with lung cancer with painful multiple bone metastases. Methods 102 patients with lung cancer with painful multiple bone metastases were randomized into combination treatment group（^153Sm - EDTMP and pamidronate）, intemal irradiation group（^153Sm - EDTMP alone） and pamidronate treatment group（pamidronate alone）. Relief of bone pain and all toxieities were observed. Results Total effective rate of combination treatment group was 91.4 %, those of internal irradiation group 68, 6 %, and pamidronate treatment group 65.6 %, which was more higher than the other two, showing a significant difference（ P 〈 0.05）. No serious toxieities were observed in all groups. Conclasion ^153Sm - EDTMP combined with pamidronate was more effective and with less toxieities to treat patients with lung cancer with painful multiple bone metastases, whlch was considered to be more widely applied.

关 键 词：肺癌 骨转移疼痛 ^153Sm-EDTMP联合帕米腾酸二钠 

分 类 号：R734.2[医药卫生—肿瘤]